Editorial |
Featured
-
-
-
News Feature |
Vaccines: The real issues in vaccine safety
Hysteria about false vaccine risks often overshadows the challenges of detecting the real ones.
- Roberta Kwok
-
-
News |
Therapeutic success stifles medical progress
Drug development loses momentum as patients shun clinical trials for tried and tested treatments. Could payment for participation be the answer?
- Heidi Ledford
-
News Feature |
Stem cells: The growing pains of pluripotency
The field of induced pluripotent stem cells has grown up fast. Now it is entering the difficult stage.
- Erika Check Hayden
-
Review Article |
Molecular mechanisms and clinical applications of angiogenesis
- Peter Carmeliet
- & Rakesh K. Jain
-
Review Article |
Progress and challenges in translating the biology of atherosclerosis
- Peter Libby
- , Paul M Ridker
- & Göran K. Hansson
-
News |
Reprogrammed cells repair damaged livers
Proof-of-principle study could point the way to averting the need for liver transplants.
- Heidi Ledford
-
Career Brief |
NIH spared budget slash
Federal grants won't evaporate for US biomedical researchers in 2011.
-
News & Views |
To the rescue of the failing heart
Heart failure is characterized by weakened contractions of heart muscle. A drug that directly activates the key force-generating molecule in this muscle may be a valuable tool to strengthen the failing heart.
- Donald M. Bers
- & Samantha P. Harris
-
News |
US stem-cell funding ban overturned
Appeals court decision bodes well for continued NIH support of controversial research.
- Meredith Wadman
-
Spotlight |
Spotlight on Texas
-
Comment |
The rise of people power
Calls in Canada for trials of a contentious treatment for multiple sclerosis illustrate how social media can affect research priorities, say Roger Chafe and his colleagues.
- Roger Chafe
- , Karen B. Born
- & Andreas Laupacis
-
News |
California ponders cell-banking venture
State agency grapples with technical and ethical challenges.
- Erika Check Hayden
-
News |
New drug targets raise hopes for hepatitis C cure
As the first targeted therapies edge towards regulatory approval, attention turns to the next drugs in line.
- Heidi Ledford
-
Research Highlights |
Stubborn virus grows in sinus
-
News & Views |
Remarkable role for the placenta
The placenta does not only act as the essential link between the developing embryo and its mother. Unexpectedly, it is also a source of serotonin — a neurotransmitter that is crucial for embryonic brain development. See Letter p.347
- Ron McKay
-
News Feature |
Neuroscience: Brain buzz
Scientists reviving a decades-old technique for brain stimulation have found that it can boost learning. So what else can be done with some wires and a nine-volt battery?
- Douglas Fox
-
News |
Australian medical researchers on the march
Rumours of drastic cuts to research budget spark protests.
- James Mitchell Crow
-
Feature |
California: Safe harbour
San Diego's diverse corporate science portfolio offers opportunities for open-minded scientists hoping to escape stagnation in academia.
- Karen Kaplan
-
News & Views |
The diet–microbe morbid union
A common dietary component that some people even take as a supplement is converted by the gut microbiota to harmful metabolites linked to heart disease. This finding has cautionary implications. See Article p.57
- Kimberly Rak
- & Daniel J. Rader
-
News |
Stem cells make 'retina in a dish'
Mouse cells have been coaxed into forming a retina, the most complex tissue yet engineered.
- Ewen Callaway
-
News |
Patent dispute threatens US Alzheimer's research
Lawsuit could expose hundreds of scientists to property-rights litigation.
- Erika Check Hayden
-
News |
Rare-disease project has global ambitions
Consortium aims for hundreds of new therapies by 2020.
- Alison Abbott
-
News |
Muscular dystrophy findings fuel French stem cell debate
Work shows the value of human embryonic stem cells for disease research.
- Alison Abbott
-
Technology Feature |
A living system on a chip
For years, scientists have struggled to reconstruct tissues and organs by combining cells and nanotechnology. These devices are now edging from cool concept to practical application.
- Monya Baker
-
Comment |
Time to rethink the NIH
A radical restructure is the only way to solve the systemic problems of the world's biggest funder of biomedical research, argues Michael M. Crow.
- Michael M. Crow
-
News |
NIH firm on grant application rules
Unpopular policy limiting applicants to two submissions has sped up approvals.
- Meredith Wadman
-
-
-
-
Career Brief |
Disheartening cuts
US biomedical research risks losing top talent, says NIH director.
-
Research Highlights |
Skeleton boosts stud quotient
-
Feature |
Cancer research: Promise of protection
Cancer vaccines have long shown lots of potential but few results. Signs of success now suggest opportunities.
- Kelly Rae Chi
-
Outlook |
Introduction: The prevention agenda
Despite our relative wealth of knowledge about the causes of cancer, the disease persists — and the burden is worsening. Prevention demands political will, ample funding and a change in mindset.
- Tiffany O'Callaghan
-
News & Views |
In vitro sperm maturation
Anticancer therapies can impair male fertility. Whereas men can opt to freeze their sperm before treatment, young boys don't produce mature sperm and so lack this choice. Work in mice offers hope for such patients. See Letter p.504
- Marco Seandel
- & Shahin Rafii
-
News Feature |
Cancer: Missing the mark
Why is it so hard to find a test to predict cancer?
- Lizzie Buchen
-
Editorial |
Cause for concern
Scientists studying diseases should be motivated by patients, but not led by them.
-
News |
Europe rules against stem-cell patents
Work with human embryonic stem cells is 'contrary to ethics'.
- Alison Abbott
-
News & Views |
Progesterone's gateway into sperm
The hormone progesterone rapidly activates intracellular signalling in human sperm, regulating key aspects of their physiology. An ion channel unique to the sperm tail seems to relay progesterone's signal. See Letters p.382 & p.387 See Clarification p.598
- Steve Publicover
- & Christopher Barratt
-
News & Views |
Cancer lessons from mice to humans
New clinical trials report the efficacy of two mechanism-based therapies for treating human pancreatic neuroendocrine tumours. Studies in mouse models have contributed to these success stories, and continue to do so.
- David Tuveson
- & Douglas Hanahan
-
News |
Mid-career crunch
Some senior scientists feel neglected by the National Institutes of Health's grant formula.
- Kendall Powell
-
News |
Hidden toll of embryo ethics war
Federal funds continue to be withheld for stem cells derived without destroying embryos.
- Heidi Ledford
-
News Feature |
Virology: Fighting for a cause
When Judy Mikovits found links between chronic fatigue syndrome and a virus, the world took notice. Now, she's caught between the patients who believe her work and the researchers who don't.
- Ewen Callaway
-
News |
European Court of Justice rejects stem-cell patents
Researchers surprised by judge's conservative stance.
- Alison Abbott
-
News & Views |
Context is key in the gut
The vitamin-A metabolite retinoic acid normally favours immune tolerance in the gut. But in coeliac disease — an intestinal inflammatory disorder due to adverse reactivity to a dietary protein — it may do just the opposite. See Letter p.220
- Craig L. Maynard
- & Casey T. Weaver
-
-
Editorial |
The generation game
Birth-cohort studies offer invaluable data on the links between childhood development and later life, but today's efforts could learn something from a pioneering project that turns 65 this week.
-
News |
NIH revamp rushes ahead
Translational-science centre remains on the fast track, despite concerns about upheaval.
- Meredith Wadman